Acorda Therapeutics ACOR today announced that new data
from a pharmacokinetics study on Diazepam Nasal Spray found comparable
pharmacokinetics (PK) whether the drug was administered during or
immediately after a seizure. These data were presented at the 67th
Annual Meeting of the American Epilepsy Society, in Washington, D.C.
Diazepam Nasal Spray is being developed for the treatment of people with
epilepsy who experience cluster seizures, also known as acute repetitive
seizures.
“In this study, some patients received a dose of Diazepam Nasal Spray
while having a seizure, while others received the dose after their
seizure activity had ceased,” said Adrian Rabinowicz, M.D., FAAN,
Acorda's Senior Vice President of Clinical Development and Medical
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in